多重微滴式数字PCR诊断ICU疑似血流感染的临床验证:一种有前景的诊断工具
该前瞻性诊断研究于2021年5月21日至12月22日在一家综合ICU开展,对150例危重患者的438例次疑似血流感染同步行血培养与多重ddPCR(2.5小时)检测12种常见血流感染病原及3种耐药基因。血培养与ddPCR阳性分别为40例次(9.1%)与180例次(41.1%),一致280例次、不一致158例次。以血培养为参照,ddPCR各菌种敏感度58.8–86.7%(合计72.5%)、特异度73.5–92.2%(合计63.1%);ddPCR阳性/血培养阴性占33.6%(147/438),其中87.1%(128/147)与可能(108例)或疑似(20例)血流感染相关。以临床诊断血流感染为真阳性时,ddPCR最终敏感度84.9%、特异度92.5%。作者认为多重ddPCR可作为常规血培养的附加补充,结合临床感染证据有助于快速诊断疑似血流感染及耐药基因。
要点
- 438例次疑似血流感染中血培养阳性40例次(9.1%)、ddPCR阳性180例次(41.1%),ddPCR检出率明显更高。
- 以血培养为参照,ddPCR各菌种敏感度58.8–86.7%(合计72.5%),特异度73.5–92.2%(合计63.1%)。
- ddPCR阳性/血培养阴性147例次(33.6%),其中87.1%(128/147)对应可能(108例)或疑似(20例)血流感染。
- 以临床诊断血流感染为真阳性,ddPCR敏感度84.9%、特异度92.5%。
- 检出blaKPC 40例、blaNDM 3例、mecA 38例,blaKPC中90.5%为确定阳性;葡萄球菌属标本中65.8%经全部微生物学分析预测为mecA阳性。
适用人群与场景
- 一家综合ICU内疑似血流感染的危重患者,共150例、438例次疑似血流感染发作。
处置流程与药物剂量
- 对疑似血流感染患者同步采集配对血培养与多重ddPCR(2.5小时),检测12种最常见血流感染病原及3种耐药基因。
- ddPCR结果需结合临床感染证据解读:ddPCR阳性而血培养阴性时,需对照临床复合诊断判断其临床意义。
研究设计与关键结果
- 前瞻性诊断研究,2021年5月21日至12月22日在一家综合ICU开展,纳入150例危重患者的438例次疑似血流感染。
- 血培养与ddPCR对目标细菌阳性分别为40例次(9.1%)与180例次(41.1%),一致280例次、不一致158例次。
- 以血培养为参照,ddPCR各菌种敏感度58.8–86.7%(合计72.5%),特异度73.5–92.2%(合计63.1%)。
- ddPCR阳性/血培养阴性率为33.6%(147/438),其中87.1%(128/147)与可能(108例)或疑似(20例)血流感染相关。
- 以临床诊断血流感染为真阳性时,ddPCR最终敏感度84.9%、特异度92.5%。
- 检出blaKPC 40例、blaNDM 3例、mecA 38例,其中blaKPC 90.5%为确定阳性。
- 经全部微生物学分析,65.8%的葡萄球菌属标本被预测为mecA阳性。
证据类型、等级与局限
- 证据类型:前瞻性诊断研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为多重ddPCR平台灵活通用,可作为常规血培养的附加补充。
- 作者认为结合临床感染证据时,ddPCR在ICU实践中对快速诊断疑似血流感染及耐药基因显示出潜在优势。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Droplet digital PCR (ddPCR) has emerged as a promising tool of pathogen detection in bloodstream infections (BSIs) in critical care medicine. However, different ddPCR platforms have variable sensitivity and specificity for diverse microorganisms at various infection sites. There is still a lack of prospective clinical studies aimed at validating and interpreting the discrepant ddPCR results for diagnosing BSI in intensive care unit (ICU) practice.
METHODS: A prospective diagnostic study of multiplex ddPCR panels was conducted in a general ICU from May 21, 2021, to December 22, 2021. Paired blood cultures (BCs) and ddPCRs (2.5 h) were obtained synchronously to detect the 12 most common BSI pathogens and three antimicrobial resistance (AMR) genes. Firstly, ddPCR performance was compared to definite BSI. Secondly, clinical validation of ddPCR was compared to composite clinical diagnosis. Sensitivity, specificity, and positive and negative predictive values were calculated. Thirdly, the positive rate of AMR genes and related analysis was presented.
RESULTS: A total of 438 episodes of suspected BSIs occurring in 150 critical patients were enrolled. BC and ddPCR were positive for targeted bacteria in 40 (9.1%) and 180 (41.1%) cases, respectively. There were 280 concordant and 158 discordant. In comparison with BCs, the sensitivity of ddPCR ranged from 58.8 to 86.7% with an aggregate of 72.5% in different species, with corresponding specificity ranging from 73.5 to 92.2% with an aggregate of 63.1%. Furthermore, the rate of ddPCR+/BC- results was 33.6% (147/438) with 87.1% (128 of 147) cases was associated with probable (n = 108) or possible (n = 20) BSIs. When clinically diagnosed BSI was used as true positive, the final sensitivity and specificity of ddPCR increased to 84.9% and 92.5%, respectively. In addition, 40 blaKPC, 3blaNDM, and 38 mecA genes were detected, among which 90.5% were definitely positive for blaKPC. Further, 65.8% specimens were predicted to be mecA-positive in Staphylococcus sp. according to all microbiological analysis.
CONCLUSIONS: The multiplexed ddPCR is a flexible and universal platform, which can be used as an add-on complementary to conventional BC. When combined with clinical infection evidence, ddPCR shows potential advantages for rapidly diagnosing suspected BSIs and AMR genes in ICU practice.
参考来源
- Wu J, Tang B, Qiu Y, et al. Clinical validation of a multiplex droplet digital PCR for diagnosing suspected bloodstream infections in ICU practice: a promising diagnostic tool. Crit Care. 2022. PMID: 35941654. doi:10.1186/s13054-022-04116-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。